Heart Failure
Conditions
Interventions
Group C:None
Group A:Standardized Treatment+Qiliqiangxin Capsule
Group B:Standardized Treatment
Sponsors
Liaocheng People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for patients with heart failure: (1) Aged >=18 years, no gender limit; (2) Have a history of chronic heart failure for more than 18 months or have clinical findings of heart failure symptoms for more than 18 months; The diagnosis of chronic heart failure should refer to the local guidelines or the ''Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018'' issued by the Chinese Society of Cardiology; (3) Left ventricular ejection fraction (LVEF) indicated by cardiac color ultrasound = 450pg/ml(more than 12 months before enrollment); (6) Group A had received standard medicine + Qiliqiangxin Capsule for at least 12 months, without adjustment of dose and intravenous therapy; Standardized drug therapy includes: angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor antagonists (ARBs) or angiotensin-receptor enkeenase inhibitors (ARNI), beta blockers, and aldosterone receptor antagonists; Group B had received standardized drug therapy for at least 12 months without adjusting the dose and intravenous therapy; Standardized drug therapy includes: angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor antagonists (ARBs) or angiotensin-receptor enkeenase inhibitors (ARNI), beta blockers, and aldosterone receptor antagonists; (7) The patient agrees and signs the informed consent voluntarily. 2. Inclusion criteria of healthy subjects: (1) Aged >=18 years, no gender limit; (2) No history of current illness or previous history of important human systems; (3) No drugs have been taken within 1 month. Participate voluntarily, understand and agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for patients with heart failure: (1) Heart failure caused by valvular disease, congenital heart disease, pericardial disease, arrhythmia and non-cardiogenic causes, or failure of the kidney, liver and other important organs, as well as right heart failure and acute heart failure caused by definite pulmonary or other causes; (2) Patients who have recently received coronary revascularization therapy or cardiac resynchronization therapy, and patients who have received cardiac resynchronization therapy; (3) Patients with severe primary diseases of liver, kidney and hematopoietic system and abnormal renal function had liver transaminase and alkaline phosphatase exceeding 3 times the upper limit of normal value, blood creatinine > 2mg/dl(176.82umol/L) and blood potassium > 5.5mmol/L; Tumor patients, patients with severe neuroendocrine system diseases and psychiatric patients; (4) Unrepaired valvular heart disease with left ventricular outflow tract obstruction, myocarditis, large aneurysm, dissection aneurysm, and significant hemodynamic changes; (5) Patients with cardiogenic shock, uncontrolled malignant arrhythmias, second-degree type II or above sinus or atrioventricular block without pacemaker implantation, progressive aggravation of unstable angina or acute myocardial infarction; (6) Patients with uncontrolled hypertension, systolic blood pressure >=180/mmHg and/or diastolic blood pressure >=110mmHg; Systolic blood pressure <90mmHg and/or diastolic blood pressure <60mmHg; (7) Pregnant and lactating patients; (8) In the investigator's judgment, the patient was unable to complete the study or comply with the requirements of the study. 2. Exclusion criteria for healthy subjects: According to the judgment of the investigator, the subject could not complete the study or could not comply with the requirements of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation analysis of proteome and metabolome data in peripheral blood serum; | — |
Countries
China
Contacts
Public ContactSun Peng
Outcome results
None listed